Daptomycin pharmacodynamics against Staphylococcus aureus hemB mutants displaying the small colony variant phenotype

Begic, Damir; von Eiff, Christof; Tsuji, Brian T.
May 2009
Journal of Antimicrobial Chemotherapy (JAC);May2009, Vol. 63 Issue 5, p977
Academic Journal
: Objectives Staphylococcus aureus small colony variants (SCVs) are slow-growing morphological variants associated with persistent infections. While vancomycin activity has been shown to be attenuated against SCVs of S. aureus, few data exist regarding daptomycin. The objective was to evaluate the pharmacodynamics of daptomycin against defined S. aureus mutants displaying the SCV phenotype. : Methods Two S. aureus hemB mutants (Ia48 and III33) displaying the SCV phenotype and their parental strains (COL and Newman) were evaluated. Time–kill experiments were performed using a starting inoculum of 106 cfu/mL at 0, 0.25, 0.5, 1, 2, 4, 8, 16, 32 and 64 times the MIC. Samples were obtained at 0, 1, 2, 4, 6, 8 and 24 h, plated and incubated to determine colony counts. A Hill-type pharmacodynamic mathematical model was fitted to the data to characterize the effect. : Results Bactericidal activity for daptomycin was achieved and occurred in a concentration-dependent manner against both hemB mutants and their parental strains. Against strains with normal phenotype, bactericidal activity was achieved rapidly, within 2 h at concentrations ≥16 times the MIC, while against SCVs, bactericidal activity was achieved within 6 h at concentrations ≥16 times the MIC. Against both hemB mutants, daptomycin maintained bactericidal activity at 24 h, with similar profiles of killing activity when compared with their parental strains. : Conclusions Daptomycin achieved bactericidal activity against S. aureus hemB mutants and parenteral isolates. Daptomycin represents a potential therapeutic option for infections caused by S. aureus strains displaying the SCV phenotype and additional studies are warranted.


Related Articles

  • The killer bug. Shnayerson, Michael // Fortune;9/30/2002, Vol. 146 Issue 6, p149 

    Reports on a mutation of the Staphylococcus aureus (S. aureus) that is resistant to penicillin, methicillin, and vancomycin. Infection of a Michigan woman with a vancomycin-resistant strain; Effects of unstoppable infections in hospitals; Transmission of germs in hospitals; Vaccine from Nabi...

  • Vancomycin-resistant staph: First in Japan, now here. Pinkowish, Mary Desmond // Patient Care;10/15/1997, Vol. 31 Issue 16, p171 

    Focuses on the report of a case of Staphylococcus aureus isolate with reduced susceptibility to vancomycin HCl in the United States. Details of the first known case of its kind; Reference to a Japanese report on the first incident of the vancomycin-resistant staph; Issue of interim guidelines...

  • Staphylococcus aureus with Reduced Susceptibility to Vancomycin--Illinois, 1999. Khurshid, M.A.; Chou, T. // MMWR: Morbidity & Mortality Weekly Report;1/7/2000, Vol. 48 Issue 51/52, p1165 

    Describes the case of a confirmed infection of Staphylococcus aureus with reduced susceptibility to vancomycin in a woman in Illinois in April 1999. Medical history of the patient; Drugs given to the patient; Cause of death of the patient.

  • Staphylococcus aureus Resistant to Vancomycin--United States, 2002.  // MMWR: Morbidity & Mortality Weekly Report;7/5/2002, Vol. 51 Issue 26, p565 

    Presents a report on the clinical isolate of vancomycin-resistant Staphylococcus aureus (VRSA) in the U.S. in 2002. Infections caused by Staphylococcus aureus; Details of a case of VRSA isolated from a patient; Methods used in identifying VRSA isolate from the patient.

  • Daptomycin/vancomycin.  // Reactions Weekly;2/5/2011, Issue 1337, p16 

    The article describes six cases of persistent or recurrent Staphylococcus aureus bacteraemia experienced by six patients despite vancomycin and subsequent daptomycin treatment.

  • Vancomycin-heteroresistant phenotype in invasive methicillin-resistant Staphylococcus aureus isolates belonging to spa type 041. Monaco, M.; Sanchini, A.; Grundmann, H.; Pantosti, A. // European Journal of Clinical Microbiology & Infectious Diseases;Jul2010, Vol. 29 Issue 7, p771 

    The aim of this study was to characterise invasive methicillin-susceptible Staphylococcus aureus (MSSA) and methicillin-resistant S. aureus (MRSA) strains from Italy and to investigate the presence of heteroresistant vancomycin-intermediate S. aureus (h-VISA). Eighty-two MSSA and 66 MRSA strains...

  • Vancomycin Therapeutic Guidelines: A Summary of Consensus Recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Rybak, Michael J.; Lomaestro, Ben M.; Rotschafer, John C.; Moellering Jr., Robert C.; Craig, Willam A.; Billeter, Marianne; Dalovisio, Joseph R.; Levine, Donald P. // Clinical Infectious Diseases;8/1/2009, Vol. 49 Issue 3, p325 

    Practice guidelines for therapeutic monitoring of vancomycin treatment for Staphylococcus aureus infection in adult patients were reviewed by an expert panel of the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases...

  • Impact of the agr Quorum-Sensing System on Adherence to Polystyrene in Staphylococcus aureus. Cuong Vuong; Saenz, Henri L.; Gotz, Friedrich; Otto, Michael // Journal of Infectious Diseases;12/1/2000, Vol. 182 Issue 6 

    Biofilm formation by Staphylococcus aureus is a serious problem in nosocomial infections. There are great differences in the capacity of S. aureus to express biofilms, but the reasons are unknown. In all, 105 S. aureus strains were tested for a correlation between the agr quorum-sensing system...

  • Norway Stops Superbug.  // Current Science;4/16/2010, Vol. 95 Issue 15, p14 

    The article reports on the move of the Norwegian government to cut back on too much use of antibiotics for the treatment of Staphylococcus aureus infections (MRSA) among patients which have yielded into positive results and reduced the number of people infected by the bacteria.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics